The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Merck’s Keytruda has been used against dozens of ... Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF ...

The antibody – which is in phase 2 testing – is viewed as a potential successor to MSD's $25 billion PD-1 inhibitor Keytruda (pembrolizumab). It is in the same class as Summit Therapeutics and ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA ... and an alliance with Daiichi Sankyo on antibody-drug conjugates for cancer that included a whopping $4 billion upfront payment ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Keytruda is an anti–PD-1 therapy which increases the ability of the body’s immune system to help detect and fight tumor cells. Also a humanized monoclonal antibody, the agent blocks the interaction ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD- L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy ...

cetuximab in combination with MSD’s flagship monoclonal antibody Keytruda (pembrolizumab). Now, the San Diego-based company is looking to launch enrolment for the trial across Japan and Taiwan.